Trials / Completed
CompletedNCT04540705
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
A Phase 1 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| DRUG | Axitinib | Specified dose on specified days |
| DRUG | Cabozantinib | Specified dose on specified days |
Timeline
- Start date
- 2020-09-11
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
- First posted
- 2020-09-07
- Last updated
- 2024-02-28
Locations
39 sites across 8 countries: United States, Argentina, Brazil, Canada, France, Germany, Mexico, Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04540705. Inclusion in this directory is not an endorsement.